StockData
Intensity Therapeutics, Inc. logo

Intensity Therapeutics, Inc. (INTS) stock

INTSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$3.28+0.19 (+6.15%)

Close on Nov 11, 2026Market cap $10.71MP/E –Yield –

Earnings

Intensity Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 26, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
-$1.11
-$0.13 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Intensity Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 26, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026before the open–––Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026before the open––-$1.11Release
Q1 FY2026ended Mar 31, 2026May 7, 2026during market hours––-$0.96Release
Q4 FY2025ended Dec 31, 2025Mar 27, 2026during market hours–––Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours––-$0.06Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours––-$0.13Release
Q1 FY2025ended Mar 31, 2025May 13, 2025during market hours––-$0.22Release
Q4 FY2024ended Dec 31, 2024Mar 13, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 13, 2024during market hours––-$0.25Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours––-$0.36Release
Q1 FY2024ended Mar 31, 2024May 9, 2024during market hours––-$0.34Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Intensity Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Intensity Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Intensity Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
    Results
  2. Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
    Results
  3. Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    Results
  4. Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
    Results
  5. Intensity Therapeutics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
    News
  6. Updated as of March 5, 2026
    Results
  7. Intensity Therapeutics Announces Reverse Stock Split
    News
  8. Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    Results
  9. Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
    News
  10. Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
    Results
  11. Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025
    News
  12. Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
    News
  13. Intensity Therapeutics, Inc. Announces Pricing of Public Offering
    News
  14. Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
    Results
  15. Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering
    News

See a number that looks wrong?